Quantcast
Home > Quotes > ABIO
ABIO

ARCA biopharma, Inc. Common Stock (ABIO) Quote & Summary Data

$0.5579
*  
0.0113
1.99%
Get ABIO Alerts
*Delayed - data as of Apr. 20, 2018  -  Find a broker to begin trading ABIO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
2
Today's High / Low
$ 0.6055 / $ 0.552
Share Volume
219,699
50 Day Avg. Daily Volume
1,235,502
Previous Close
$ 0.5692
52 Week High / Low
$ 2.76 / $ 0.45
Market Cap
7,762,799
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-1.04

Intraday Chart

Shares Traded

Share Volume:
219,699
50 Day Avg. Daily Volume:
1,235,502

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -1.80

Trading Range

The current last sale of $0.5579 is 23.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.6055 $ 2.76
 Low: $ 0.552 $ 0.45

Company Description (as filed with the SEC)

ARCA biopharma, Inc. (the "Company" or "ARCA"), a Delaware corporation, is headquartered in Broomfield, Colorado and is principally focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator for chronic heart failure, or HF. Gencaro was the subject of a Phase 3 heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants. The Company has licensed exclusive, worldwide rights to Gencaro. In September 2008, the U.S. Food and Drug Administration ("FDA") accepted for filing the Company's New Drug Application ("NDA") for Gencaro. On May 29, 2009, the FDA issued a Complete Response Letter to the Company which stated that the FDA could not approve the Gencaro NDA in its current form and specified additional actions and information required by the FDA for approval of the NDA.  ... More ...  

Risk Grade

Where does ABIO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.5601
Open Date:
Apr. 20, 2018
Close Price:
$ 0.554
Close Date:
Apr. 20, 2018

Consensus Recommendation

Analyst Info